PHT Educational Webinar
Integrating ePRO with Glucometers:
Electronic Capture of Blood Glucose Readings in Multinational Diabetes Populations
Event Date: April 23, 2013
Time: 2:00 PM - 3:00 PM, Eastern Daylight Time, US
(Or register here to attend 10:00 AM - 11:00 AM Eastern Daylight Time, US)
In type 1 and type 2 diabetes patients, tight control of blood glucose levels reduces the risk of developing microvascular complications. Consistent glycemic control is critical for improving patient outcomes and avoiding diabetes-induced clinical sequelae.
One of the most important tools for maintaining glycemic control is the patient diary. Patient-reported outcome (PRO) and electronic PRO (ePRO) measures are standard tools for directly eliciting the patient experience for Clinical Outcome Assessments (COAs). Patient diaries are a key component for diabetes patients and their caregivers to monitor glycemic control and diet. Electronic PRO diaries and integration with glucometers shows significant advantages over paper diaries, including increased reliability and compliance, no illegible or missing data, and time/date-stamped entries.
This Webinar will review findings from multiple global diabetes programs to reveal how ePRO data via glucometer device integration:
• Obviates hypoglycemia underreporting and inaccuracies
• Generates blood glucose frequency data that conforms to a more Gaussian Distribution of continuous glucose monitoring (CGM) than paper data
• Shows an incidence rate of hypoglycemia in ePRO trials with integrated glucometers that is in line with CGM
|Who Should Attend||Learning Objectives|
|Professionals involved in:|
At the conclusion of this webinar, participants will understand:
About the Presenter
Susan M. Dallabrida, PhD
Senior Scientific Advisor
Dr. Susan Dallabrida has over 20 years of experience in clinical trial design, strategy, and research and product development in a wide range of therapeutic areas (cancer, cardiovascular disease, hemophilia, vascular disorders, obesity, and aging). She is an experienced senior scientist and project leader in R&D and has led multiple cross‐functional oncology drug discovery and product development teams and collaborations. She has 20 peer‐reviewed articles, 14 grants, 3 patents, 15 abstracts, 29 conference presentations, and 17 awards. Her awards include the Harvard Catalyst Pilot Award and David Bray Scholars in Medicine from Harvard Medical School, Young Investigator’s Awards, NIH grants (NCI, NIDDK), biotechnology/pharmaceutical sponsored funding (Genentech, Amgen, Astrazeneca), and foundational grants (American Heart Association, Heart and Stroke Foundation, Plastic Surgery Education Foundation, Leet/Guthrie Patterson Trust Foundation). Dr. Dallabrida received a B.A. in Chemistry and a B.S. in Biology, both cum laude, from Bloomsburg University; and a Ph.D. in Biochemistry and Molecular Biology from Pennsylvania State University.
This event took place on April 23, 2013 and has ended.
Please vist the Upcoming Events section of the PHT website to see the list of future events.